Personalis, Inc.

PSNL

Explore Our Financial Data > Companies > Personalis, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	PSNL
CIK	0001527753
SIC	8071
Sector	Services
Industry Category	Healthcare
Industry Group	Services – Health

Contact

Address	6600 DUMBARTON CIRCLE, FREMONT, CA, 94555
Website	personalis.com
Phone	650-752-1300
CEO	John S. West
Employees	400

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$85.69 million
Pre-Tax Income	$-84.05 million
Net Income	$-84.07 million
Net Income to Common	$-84.07 million
EPS	$-1.29

View All

Balance Sheet

Cash	$71.00 million
Assets	$273.31 million
Liabilities	$65.96 million
Common Equity	$207.34 million
Liabilities & Equity	$273.31 million

View All

Cash Flow Statement

Net Income	$-84.07 million
Cash From Operating Activities	$-42.70 million
Cash From Investing Activities	$-63.91 million
Cash From Financing Activities	$133.63 million
Change in Cash	$27.04 million

View All

Calculations

NOPAT	$-46.96 million
EBITDA	$-82.52 million
Price to Earnings	N/A
Price to Book	$2.30
ROE	-51.25%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Tempus AI (TEM) Secures FDA Clearance For ECG-Low EF Software

Tempus AI (TEM) recently secured FDA clearance for its Tempus ECG-Low EF software and expanded its collaboration with Personalis for colorectal cancer detection, measures that collectively strengthened its market position. These advances, alongside its inclusion in various Russell indices, have contributed to the company's 19% share price increase over the last quarter. During this period, broader markets, such as the S&P 500 and Nasdaq, also reached all-time highs, bolstered by easing tariff...

Article Link

Personalis to Announce Second Quarter 2025 Financial Results

FREMONT, Calif., July 22, 2025--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Article Link

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FREMONT, Calif., July 18, 2025--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on July 15, 2025, a non-qualified stock option to purchase an aggregate of 100,000 shares of its common stock to Personalis’ new Vice President, Corporate Controller under Personalis’ 2020 Inducement Plan.

Article Link

Tempus AI (TEM) Gains FDA Clearance for New Cardiovascular Risk Detection Software

Tempus AI (TEM) has recently secured FDA clearance for its Tempus ECG-Low EF software, an innovative AI-driven product aiding cardiovascular assessments. This development aligns with TEM’s aim to enhance its ECG-AI technology leadership, potentially strengthening its market position. Alongside, the company's improved Q1 earnings report, with notable revenue growth from $146 million to $256 million, reflects its robust performance. Additionally, Tempus’s expansion into new strategic...

Article Link

Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer

Given the company’s popularity among hedge funds and the bullish sentiment surrounding it, Tempus AI, Inc. (NASDAQ:TEM) makes it to our list of the Top 10 AI Infrastructure Stocks to Buy Now. On July 10, 2025, Tempus AI, Inc. (NASDAQ:TEM) announced an update about its strategic partnership with Personalis. Under this expansion, the company added […]

Article Link